Literature DB >> 971699

Metabolism of digitoxin in man and its modification by spironolactone.

K E Wirth, J C Frölich, J W Hollifield, F C Falkner, B S Sweetman, J A Oates.   

Abstract

The effect of spironolactone on the metabolism of intravenously administered 3H-digitoxin (80 muCi) was investigated in eight patients. In three of them the labelled glycoside was given on a second occasion after spironolactone treatment had been discontinued for at least 65 days. Of total urinary radioactivity 79% was unaltered drug and 12% consisted of water soluble compounds. No digitoxigenin or digoxigenin and only trace amounts (less than 2 %) of digoxin and the bis- and monoglycosides of digoxigenin were found. After spironolactone total urinary radioactivity was unchanged but the fraction eliminated as unchanged digitoxin fell from 79 to 66 % and the water soluble compounds increased from 12 to 26 % (p less than 0.05). In addition spironolactone caused a 20 ( reduction in the half-life of serum radioactivity (p less than 0.01) and a 16 % reduction in the volume of distribution (p less than 0.05). Induction of hepatic enzymes by spironolactone is proposed to explain the alteration in the metabolism of digitoxin in man. Both the altered metabolic pattern and the reduction in the volume of distribution appear to contribute to the reduction in half-life.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971699     DOI: 10.1007/BF00606547

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Investigation of the effects of methyltestosterone, cortisone and spironolactone on the hepatic microsomal mixed function oxidase system in male and female rats.

Authors:  M E Hamrick; N G Zampaglione; B Stripp; J R Gillette
Journal:  Biochem Pharmacol       Date:  1973-02-01       Impact factor: 5.858

2.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

3.  Studies on digitalis. I. Renal excretion of digitoxin and its cardioactive metabolites.

Authors:  L Storstein
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

Review 4.  New information regarding digitalis metabolism.

Authors:  J E Doherty; W H Hall; M L Murphy; O W Beard
Journal:  Chest       Date:  1971-04       Impact factor: 9.410

5.  Display-oriented data system for multiple ion detection with gas chromatography-mass spectrometry in quantifying biomedically important compounds.

Authors:  J T Watson; D R Pelster; B J Sweetmen; J C Frolich; J A Oates
Journal:  Anal Chem       Date:  1973-10       Impact factor: 6.986

6.  [Serum concentration and excretion of H3Y digitoxin in humans under normal and pathologic conditions].

Authors:  H Lahrtz; H M Reinold; P A van Zwieten
Journal:  Klin Wochenschr       Date:  1969-07-01

7.  Some aspects of the distribution and disposition of digitoxin in man.

Authors:  D S Lukas
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

8.  Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication.

Authors:  B Solymoss; S Toth; S Varga; H Selye
Journal:  Toxicol Appl Pharmacol       Date:  1971-03       Impact factor: 4.219

9.  Excretion of 3H-digitoxin and its metabolites following spironolactone pretreatment in rats.

Authors:  M C Castle; G L Lage
Journal:  Drug Metab Dispos       Date:  1973 May-Jun       Impact factor: 3.922

10.  Double isotope dilution derivative assay of digitoxin in plasma, urine, and stool of patients maintained on the drug.

Authors:  D A Lukas; R E Peterson
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

View more
  12 in total

1.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 3.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

5.  [The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].

Authors:  J P Masson; O Bass; H R Baur; E E Ohnhaus
Journal:  Klin Wochenschr       Date:  1978-11-01

6.  Pharmacokinetics and bioavailability of digitoxin by a specific assay.

Authors:  R T MacFarland; F I Marcus; P E Fenster; P E Graves; D Perrier
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Cleavage of digoxigenin digitoxosides by rat liver microsomes.

Authors:  A Schmoldt; B Ahsendorf
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

Review 9.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

10.  Inhibition by basic drugs of digoxin secretion into human bile.

Authors:  A Hedman
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.